KMT2E

Across TCGA pan-cancer cohorts, KMT2E Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated KMT2E data layer compared with 28 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher KMT2E Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KMT2E expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, LUSC, and READ are the cancer types where KMT2E Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.141	0.788	<.001	24	view →
LUSC	OS	Median	IV	0.001	0.673	.014	12	view →
READ	DFS	Median	III,IV	0.255	0.757	.008	9	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
UCEC	DFS	Median	All	0.901	0.622	.023	4	view →
SKCM	OS	Median	All	0.662	0.790	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

KMT2E–LUAD (OS)

Open the LUAD breakdown →